Christine Walchuk is an associate in the firm’s Technology & Life Sciences Group. She joined Goodwin in 2015. 

Ms. Walchuk’s practice focuses on the representation of public and private life sciences companies in a broad range of commercial and intellectual property transactions. She advises clients regularly with respect to complex commercial transactions designed to maximize the value of pharmaceutical products and technology assets, including research and development collaborations, technology licenses and acquisitions, distribution and manufacturing agreements, and profit-sharing and co-promotion arrangements. Ms. Walchuk also counsels clients in connection with private financings, public offerings, spin-outs and M&A transactions with respect to intellectual property rights and operational risks.

In addition, Ms. Walchuk has specific experience counseling clients in strategic partnering and licensing transactions in various sectors of the agricultural biotechnology and plant sciences space, as well as clients in high-tech, software and Internet industries.

Experience

ERFAHRUNG

工作经历

Some of Ms. Walchuk’s recent representative matters include:

  • Pieris Pharmaceuticals in its collaboration with Servier for the dual-checkpoint inhibitor PRS-332 and up to seven other immuno-oncology bispecific drug candidates, for a deal value of up to €1.7 billion
  • Teva Pharmaceuticals in its global agreement with Regeneron to develop and commercialize the phase 3 novel nerve growth factor antibody fasinumab and to share in its global commercial value, for $250 million upfront and the payment of ongoing R&D costs of approximately $1 billion
  • Intellia Therapeutics in its multi-year collaboration with Regeneron on CRISPR/Cas gene-editing technology for in vivo therapeutic development, with $75 million upfront and potential milestone and royalty payments
  • Padlock Therapeutics in its sale to Bristol-Myers Squibb, valued up to $600 million with up-front and near-term payments of $225 million
  • Poseida Therapeutics, Inc. in its global agreement with Janssen to apply Centyrin technology in the development of chimeric antigen receptor (CAR) therapies*
  • Transposagen Biopharmaceuticals in its research collaboration and global license agreement with Janssen for allogeneic chimeric antigen receptor (CAR) T-cell therapies, with up to $292 million per CAR-T therapeutic in upfront and potential milestone payments in addition to potential royalty payments*

* Denotes experience prior to joining Goodwin.

Professional Experience

Prior to joining Goodwin, Ms. Walchuk was an associate in the Life Sciences practice group at Cooley LLP. She is a member of the Virginia State Bar and the American Bar Association.

In The News

MELDUNGEN

在新闻中

Credentials

WERDEGANG

专业资格

Education

J.D., Intellectual Property, 2008
University of Richmond Law School

(cum laude)

B.S., Human Biology, 2002
University of Montana

(highest honors)

Admissions

Bar

District of Columbia
Virginia
Get In Touch
KONTAKT
Get In Touch
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
搜寻其他律师